An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

Shares of Schrödinger soared by 15% mid-day Tuesday as the company, known for leveraging quantum mechanics in medicine and material design, embraces artificial intelligence (AI) to enhance its drug ...

Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of ...

Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the ...

Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

The GLP-1 drug ... Eli Lilly's market share over time. For example, Amgen (AMGN) is developing MariTide and Pfizer (PFE) is developing oral GLP-1 candidates. Again, the similarity to Nvidia in AI ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... “See, I’m thinking that Lilly’s wonder drug Mounjaro, also known as Zepbound, has way too many potential ...